Skip to main content
SpringerLink
Log in

Expression of ADAM8 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

ADAM8 behaves as an active metalloprotease in vitro, hydrolyzing myelin basic protein and a variety of peptide substrates based on the cleavage sites of membrane-bound cytokines, growth factors, and receptors. Other studies have demonstrated overexpression of some ADAM family proteins in a variety of human tumors, but no report is available on the actual expression of ADAM8 and the correlation between clinicopathologic features and prognosis of hepatocellular carcinoma (HCC) patients. In this study, serum levels of ADAM8 were measured by ELISA in 126 patients with HCC, 50 patients with liver cirrhosis (LC), and 50 healthy individuals. The expression of ADAM8 in liver tissue was further studied using Western blotting in 126 patients with HCC and 50 with LC. The correlations between ADAM8 status and various clinicopathological parameters including survival were analyzed. Survival analysis was performed using the Kaplan–Meier method and Cox's proportional hazards model. The ELISA assay showed that the serum levels of ADAM8 in the HCC, LC, and healthy groups were 136.4 ± 34.5, 64.2 ± 20.1, and 63.2 ± 22.7 U/ml, respectively. Analysis of variance was used for inter-group comparison, and differences were found between the HCC group and the other two groups (both P < 0.001), while no difference was found between the LC group and the healthy group (P = 0.365). Western blotting assay showed that ADAM8 protein expression was detected in 62.7 % (79/126) HCC and in 32 % (16/50) LC tissues. Further, ADAM8 expression was associated closely with serum AFP elevation, tumor size, histological differentiation, tumor recurrence, tumor metastasis, and tumor stage. Kaplan–Meier survival analysis showed that patients with ADAM8-positive tumors had a shorter postoperative survival time than those with ADAM8-negative tumors (P < 0.001). Multivariate analysis revealed that ADAM8 expression was an independent prognostic parameter for the overall survival rate of HCC patients. These findings provide evidence that the expression of ADAM8 serves as a poor prognostic biomarker for HCC. ADAM8 may be a potential target of antiangiogenic therapy for HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009;3:353–67. doi:10.1586/egh.09.35.

    Article  PubMed  Google Scholar 

  2. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreatol Dis Int. 2008;7:237–57.

    Google Scholar 

  3. Koorey D. Hepatocellular carcinoma: prevention, detection and treatment in the real world. Intern Med J. 2007;37:513–5. doi:10.1111/j.1445-5994.2007.01439.x.

    Article  PubMed  CAS  Google Scholar 

  4. Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, et al. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2008;8:1623–41. doi:10.1586/14737140.8.10.1623.

    Article  PubMed  CAS  Google Scholar 

  5. Yoshiyama K, Higuchi Y, Kataoka M, Matsuura K, Yamamoto S. CD156 (human ADAM8): expression, primary amino acid sequence, and gene location. Genomics. 1997;41:56–62. doi:org/10.1006/geno.1997.4607.

    Article  PubMed  CAS  Google Scholar 

  6. Yamamoto S, Higuchi Y, Yoshiyama K, Shimizu E, Kataoka M, Hijiya N, et al. ADAM family proteins in the immune system. Immunol Today. 1999;20:278–84. doi:10.1016/S0167-5699(99)01464-4.

    Article  PubMed  CAS  Google Scholar 

  7. Schlomann U, Wildeboer D, Webster A, Antropova O, Zeuschner D, Knight CG, et al. The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. Biol Chem. 2002;277:48210–9. doi:10.1074/jbc.M203355200.

    Article  CAS  Google Scholar 

  8. Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet. 2000;16:83–7. doi:org/10.1016/S0168-9525(99)01926-5.

    Article  PubMed  CAS  Google Scholar 

  9. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003;17:7–30. doi:10.1101/gad.1039703.

    Article  PubMed  CAS  Google Scholar 

  10. Fourie AM, Coles F, Moreno V, Karlsson L. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem. 2003;278:30469–77. doi:10.1074/jbc.M213157200.

    Article  PubMed  CAS  Google Scholar 

  11. Naus S, Richter M, Wildeboer D, Moss M, Schachner M, Bartsch JW. Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem. 2004;279:16083–90. doi:10.1074/jbc.M400560200.

    Article  PubMed  CAS  Google Scholar 

  12. Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin MF, et al. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol. 2003;23:1365–71.

    PubMed  CAS  Google Scholar 

  13. O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer. 2003;105:754–61. doi:10.1002/ijc.11161.

    Article  PubMed  Google Scholar 

  14. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer. 1993;72:2979–85.

    Article  PubMed  CAS  Google Scholar 

  15. Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–8.

    PubMed  CAS  Google Scholar 

  16. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341–53.

    Article  PubMed  Google Scholar 

  17. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993;53:61–6.

    PubMed  CAS  Google Scholar 

  18. Miyake Y, Kodama T, Yamaguchi K. Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res. 1994;54:2136–40.

    PubMed  CAS  Google Scholar 

  19. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998;79:502–8. doi:10.1002/(SICI)1097-0215(19981023.

    Article  PubMed  CAS  Google Scholar 

  20. Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol. 1999;17:1802–8.

    PubMed  CAS  Google Scholar 

  21. Peng SY, Lai PL, Chu JS, Lee PH, Tsung PT, Chen DS, et al. Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology. 1993;17:35–41.

    Article  PubMed  CAS  Google Scholar 

  22. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 2000;157:763–70.

    Article  PubMed  CAS  Google Scholar 

  23. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998;79:127–32. doi:10.1002/(SICI)1097-0215 (19980417.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was funded by research grants from Wuxi Health Bureau (no. 2011312).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of General Surgery, Yixing People’s Hospital, No. 75, Tongzhen Guan Rd, Yixing, 214200, China

    Chao Jiang, Yun Zhang, Hai-Feng Yu, Xiao-Tian Yu & Su-Jun Zhou

  2. Department of Cardiothoracic Surgery, Yixing People’s Hospital, No. 75, Tongzhen Guan Rd, Yixing, 214200, China

    Yong-Fei Tan

Authors
  1. Chao Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hai-Feng Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiao-Tian Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Su-Jun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yong-Fei Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Su-Jun Zhou or Yong-Fei Tan.

Additional information

Chao Jiang, Yun Zhang, and Hai-Feng Yu contributed equally to this paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jiang, C., Zhang, Y., Yu, HF. et al. Expression of ADAM8 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Tumor Biol. 33, 2167–2172 (2012). https://doi.org/10.1007/s13277-012-0477-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0477-1

Keywords

Search

Navigation